e.l.f. Beauty stock plummets 20% as revenue and guidance fall short of expectations
Investing.com - Barclays raised its price target on Siemens Healthineers (ETR:SHL) (OTC:SEMHF) stock to EUR64.00 from EUR62.00 while maintaining an Overweight rating ahead of key upcoming catalysts.
The investment bank highlighted an "exciting catalyst pathway" for the medical technology company over the coming month, including the Siemens AG Capital Markets Day on November 13, where clarity is expected on its ownership stake in Healthineers.
Barclays anticipates the removal of a potential overhang from a large liquidity event, allowing investor focus to shift to fundamentals during Healthineers’ own Capital Markets Day on November 17, where the company may address the future of its diagnostics franchise and growth potential in imaging.
The firm specifically conducted a deep dive into photon counting technology, forecasting it could become approximately a EUR2.5 billion business by fiscal year 2030, potentially driving an incremental 1 percentage point of imaging growth in 2028.
Barclays raised its estimates for Siemens Healthineers by approximately 3%, positioning its adjusted EBIT forecasts about 2-5% ahead of consensus estimates for fiscal years 2026-2030, while continuing to view the stock as "preferred" in European medical technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.